Publications by authors named "H Hubmann"
Article Synopsis
- Cancer can lead to serious kidney issues in children requiring kidney replacement therapy (KRT), with a study identifying 287 pediatric KRT patients who had a history of cancer.
- The study showed that those whose cancer caused KRT had a longer wait for kidney transplantation compared to matched controls, with a median time of 2.4 years for cancer patients versus shorter times for controls.
- While childhood cancer survivors experienced increased mortality rates while on KRT (16% for group 1 and 23% for group 2) compared to controls, their long-term survival rates after kidney transplantation were similar to non-cancer patients.
Background: Data on comorbidities in children on kidney replacement therapy (KRT) are scarce. Considering their high relevance for prognosis and treatment, this study aims to analyse the prevalence and implications of comorbidities in European children on KRT.
Methods: We included data from patients <20 years of age when commencing KRT from 2007 to 2017 from 22 European countries within the European Society of Paediatric Nephrology/European Renal Association Registry.
In primary hyperoxaluria type 1 excessive endogenous production of oxalate and glycolate leads to increased urinary excretion of these metabolites. Although genetic testing is the most definitive and preferred diagnostic method, quantification of these metabolites is important for the diagnosis and evaluation of potential therapeutic interventions. Current metabolite quantification methods use laborious, technically highly complex and expensive liquid, gas or ion chromatography tandem mass spectrometry, which are available only in selected laboratories worldwide.
View Article and Find Full Text PDFBackground: Many centers accept a minimum body weight of 10 kg as threshold for kidney transplantation (Tx) in children. As solid evidence for clinical outcomes in multinational studies is lacking, we evaluated practices and outcomes in European children weighing below 10 kg at Tx.
Methods: Data were obtained from the European Society of Paediatric Nephrology/European Renal Association and European Dialysis and Transplant Association Registry on all children who started kidney replacement therapy at <2.
Background: Management of pediatric post-transplantation lymphoproliferative disorder (PTLD) after hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) is challenging.
Aim: This study of 34 PTLD patients up to 19-years old diagnosed in Austria from 2000 to 2018 aimed at assessing initial characteristics, therapy, response, and outcome as well as prognostic markers of this rare pediatric disease.
Methods And Results: A retrospective data analysis was performed.